Global Data release new market report forecasting the potential opportunities in the Neuropathic Pain Market

GlobalData, the industry analysis specialist’s new report, “Neuropathic Pain - Pipeline Assessment and Market Forecasts to 2016”, is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior and increased uptake of the current products. The diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists unmet needs. There exists a market potential for any new entrant that will cater for these unmet needs. There is enormous opportunity for any drug that could match or better the efficacy provided by the current players with increased safety.
GlobalData analyzed that there are over 139 molecules in various stages of the pipeline. Vimpat and Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some promising molecules such as Ralfinamide, NP-1 and Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot tolerate the available drugs. The newer therapies may intensify the existing competition and there seems to be the possibility of price war.

The Neuropathic Pain Market is Forecast to Show Modest Growth until 2016
GlobalData estimated the global neuropathic pain market to be valued at $5.5 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 0.2% from $5.5 billion in 2009 to $5.6 billion in 2016. The neuropathic pain market is driven or supported by the ageing population, increased treatment seeking behavior and increased uptake of the current agents. A low diagnosis rate and the patent expiry of Cymbalta (Duloxetine) (2013) and Lidoderm (Lidocaine patch) (2015) act as barriers for the neuropathic pain market. Pfizer remains the market leader globally.

Further Information: http://www.marketreports.com/reports/Pain.html#a2134